Blazing Star Merger Sub completes Walgreens debt tender offer
DUBLIN - Dalata Hotel Group PLC (ISE:DHG, LSE: DAL), a prominent hotel operator, has unanimously rejected a non-binding proposal from Pandox AB and Eiendomsspar AS, collectively known as the Pandox Consortium. The offer was to acquire all issued and to be issued share capital of Dalata for 605 cents per share, which the Board believes significantly undervalues the company and its future prospects.
The Board, alongside its advisers, has been conducting a Formal Sales Process (FSP) since March 6, 2025, as part of a Strategic Review aimed at enhancing shareholder value and optimizing capital opportunities. The Pandox Consortium, which is not part of the FSP having declined to participate, now has until 5:00pm on July 15, 2025, to either announce a firm intention to make an offer in compliance with the Irish Takeover Rules or to declare no intention to bid, as per the Irish Takeover Panel’s regulations.
Dalata continues to engage in discussions with several parties who have expressed initial interest in the FSP. These ongoing talks are part of the company’s commitment to its Strategic Review, with further announcements to be made as deemed appropriate.
The Board has advised shareholders to take no action in relation to the Pandox Possible Offer. The announcement by Dalata is based on a press release statement and does not indicate any firm offer or guarantee that a transaction will occur as a result of the FSP. The hotel group remains in an offer period as defined by the Irish Takeover Rules.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.